ALT Panel A shows the incidence of a composite of death from any cause, stroke, or myocardial infarction (the primary outcome). Panel B shows the incidence of major bleeding (the major secondary outcome), which was defined as a bleeding event of Bleeding Academic Research Consortium type 3 (nonfatal major bleeding) or 5 (fatal bleeding).

ALT This image shows two forest plots titled "Primary Outcome" and "Major Secondary Outcome," comparing monotherapy and DAPT across various subgroups. Each plot features a list of subgroups with corresponding hazard ratios and confidence intervals. The plots compare effectiveness between monotherapy and DAPT.

ALT The figure is a graph showing the cumulative incidence of the primary outcome (a composite of cardiovascular death, myocardial infarction, or ischemic stroke) in the milvexian group and the placebo group.

ALT A figure from the Original Article "Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI." The trial name, PREMIUM, is in parentheses after the title. The figure shows the incidence of a composite of death from any cause, stroke, or myocardial infarction (the primary outcome). The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.